Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Market Cap to Ebitda for ATE Citagenix

<< Previous

Bullboard Posts

Next >>

Comment by Scotchnoiceon Aug 11, 2021 3:16am

128 Views

Post# 33683441

RE:Market Cap to Ebitda for ATE Citagenix

3 million EBIDTA in FY21?... I see a net loss before tax of 600k coming after a long history of losses over 1mmilion per year. Citagenix has been loosing millions since ATE took controle of this company.

Citagenix is not a pharma and doesnt' manufacture anything, only purchaising products from various manufacturers and selling them to end users or distributors. Their model is pretty simple but they are loosing money, a lot of money, so something must be wrong.

1x annual revenue would be a good deal for ATE.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload